Health: Africa mobilises to produce local vaccines
An impressive assembly of personalities, including Macky Sall, Nana Akufo-Addo, Moussa Faki, Adesina, and Ursula Von der Leyen, gathered to celebrate the launch of an ambitious project in Africa: vaccine production on the continent, for the continent, and at an affordable cost.
The central goal of this initiative is to address Africa’s specific vaccine needs by producing high-quality doses at an accessible price.
The pandemic has highlighted glaring inequalities in vaccine access in Africa, prompting the African Union to take decisive action.
Rwanda’s President, Paul Kagame, emphasized the African Union’s firm commitment to no longer be vulnerable to such situations, seeking to ensure equitable access to vaccines.
To realize this vision, it is essential to establish a comprehensive ecosystem, as explained by Ugur Sahin, CEO of the German biotechnology company, BioNTech.
The aim is to ensure that facilities meet global standards while developing new drugs tailored to regional needs.
BioNTech, actively involved in researching and developing vaccines for complex diseases such as malaria, tuberculosis, HIV, and monkeypox, plays a crucial role in realizing this vision.
However, the path to local vaccine production in Africa is still a demanding journey.
Ugur Sahin hopes to begin the validation process for the first test vaccines by 2025.
In parallel, BioNTech is expanding its efforts to develop similar infrastructure in Senegal, Ghana, and South Africa.
This ambitious project reflects the collective determination to strengthen Africa’s health autonomy and eliminate disparities in access to medical treatments.
By joining forces, African nations and international partners are paving the way for a future where vaccine production on the continent contributes to the overall health of the African population.
Yann ETERNEL
